NCT Number: NCT04104893
Phase: Phase 2
Trial Summary: The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) char – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym: CHOMP
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives